公开(公告)号：US06787135B2

公开(公告)日：2004-09-07

申请号：US10096568

申请日：2002-03-13

申请人： Michael T. Trese ,  George A. Williams ,  Michael Hartzer ,  Wendelin Dailey

发明人： Michael T. Trese ,  George A. Williams ,  Michael Hartzer ,  Wendelin Dailey

IPC分类号： A61K3848

CPC分类号： A61K38/484

摘要： Methods of modifying total MMP activity levels in the vitreous of an eye are provided. In a preferred embodiment, the method results in reduced MMP activity and comprises introducing plasmin into the vitreous of the eye. Enzyme assisted vitrectomy procedures are also provided, and comprise introducing plasmin into the vitreous in an amount sufficient to induce posterior detachment of the vitreous, mechanically detaching the vitreous from the eye, introducing a replacement fluid into the eye, and introducing plasmin into the eye in an amount sufficient to decrease the total MMP activity in vitreous. Considering the purported roles of MMPs in a variety of vitreal pathologies, the present invention provides methods of inhibiting the progression of various disease conditions, including prolifertaive diabetic retinopathy.

摘要翻译： 提供了改善眼睛玻璃体总MMP活性水平的方法。 在优选的实施方案中，该方法导致MMP活性降低，并且包括将纤溶酶导入眼睛的玻璃体。 还提供了酶辅助的玻璃体切除术，并且包括将纤维蛋白溶胶引入玻璃体中，其量足以引起玻璃体的后脱离，机械地将玻璃体从眼睛中分离出来，将更换的流体引入眼中，并将纤溶酶引入眼中 足以降低玻璃体中总MMP活性的量。 考虑到MMP在各种玻璃体病变中的作用，本发明提供了抑制各种疾病状况（包括增生性糖尿病性视网膜病变）进展的方法。